Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD)

Bibliography

• Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder. Nat Rev Neurosci 2002;3:617-28
   PubMed Web of Science ®Google Scholar
• Nigg JT. Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol Psychiatry 2005;57:1424-35
   PubMed Web of Science ®Google Scholar
• Sonuga-Barke EJ. Psychological heterogeneity in AD/HD – a dual pathway model of behaviour and cognition. Behav Brain Res 2002;10:29-36
   Google Scholar
• Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237-48
   PubMed Web of Science ®Google Scholar
• Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2:104-13
   PubMedGoogle Scholar
• Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2008. Vital Health Stat 2009;(244):1-81
   Google Scholar
• Barbaresi WJ, Katusic SK, Colligan RC, Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr 2007;28(4):265-73
   Google Scholar
• Cuffe SP, Moore CG, McKeown R. ADHD and health services utilization in the national health interview survey. J Atten Disord 2009;12(4):330-40
   Google Scholar
• Pliszka SR. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1385-90
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005;57:1377-84
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Scahill L, Findling RL. Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol 2007;17:393-406
   PubMed Web of Science ®Google Scholar
• Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000;9:573-603
   PubMed Web of Science ®Google Scholar
• Lang HC, Scheffler RM, Hu TW. The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994–2003—A global pharmaceutical data analysis. Health Policy 2010: published online 10 April 2010, doi:10.1016/j.healthpol.2010.03.005
   Google Scholar
• NICE implementation uptake report: Attention deficit hyperactivity disorder (ADHD), management of ADHD in children, young people and adults December 2009. Available from: www.nice.org.uk/media/032/FA/UptakeReportADHD.pdf [Last accessed 30 June 2010]
   Google Scholar
• NICE clinical guideline 72 Attention deficit hyperactivity disorder September 2008. Available from: www.nice.org.uk/CG072 [Last accessed 30 June 2010]
   Google Scholar
• Commercial and Pipeline Insight – ADHD; Immature adult market continues to offer greatest commercial potential 2008. Available from: www.companiesandmarkets.com/Summary-Market-Report/30347.asp [Last accessed 6 June 2010]
   Google Scholar
• Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009;23(Suppl 1):21-31
   Google Scholar
• Strattera. Manufacturer's Prescribing Information (2008). Indianapolis, IN: Eli Lilly; 2008
   Google Scholar
• ClinicalTrials.gov. Available from: www.clinicaltrials.gov [Last accessed 25 May 2010]
   Google Scholar
• Boellner SW, Pennick M, Fiske K, Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy 2007;27(9):1253-62
   Google Scholar
• Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988;8:4287-98
   PubMed Web of Science ®Google Scholar
• Levy F. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav Brain Funct 2008;4:12
   PubMed Web of Science ®Google Scholar
• Easton N, Shah YB, Marshall FH, Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast. Psychopharmacology 2006;189:369-85
   Google Scholar
• Avery RA, Franowicz JS, Studholme C, The alpha-2-A-adrenoreceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 2000;23:240-9
   PubMed Web of Science ®Google Scholar
• Swartz BE, Kovalik E, Thomas K, The effects of an alpha-2 adrenergic agonist, guanfacine, on rCBF in human cortex in normal controls and subjects with focal epilepsy. Neuropsychopharmacology 2000;23:263-75
   PubMedGoogle Scholar
• Ramos BP, Stark D, Verduzco L, alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem 2006;13(6):770-6
   Google Scholar
• Wang M, Ramos BP, Paspalas CD, Alpha 2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007;129(2):397-410
   Google Scholar
• Arnsten AF. Catecholamine and second messenger influences on prefrontal cortical networks of ‘representational knowledge’: a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex 2007;17(Suppl 1):i6-15
   Google Scholar
• Li BM, Mei ZT. Delayed-response deficit induced by local injection of the alpha 2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neural Biol 1994;62(2):134-9
   Google Scholar
• Ma CL, Qi XL, Peng JY, Li BM. Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha 2-adrenoceptors in monkeys. Neuroreport 2003;14(7):1013-16
   Google Scholar
• Ma CL, Arnsten AF, Li BM. Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. Biol Psychiatry 2005;57(2):192-5
   Google Scholar
• Kiechel J. Pharmacokinetics and metabolism of guanfacine in man: a review. Br J Clin Pharmacol 1980;10(Suppl 1):25S-32S
   Google Scholar
• INTUNIV. Manufacturer's Prescribing Information (2009). Shire, Wayne, PA; 2010
   Google Scholar
• Swearingen D, Pennick M, Shojaei A, A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther 2007;29(4):617-25
   Google Scholar
• Biederman J, Melmed RD, Patel A, A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008;121(1):e73-84
   Google Scholar
• Sallee FR, McGough J, Wigal T, Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48(2):155-65
   Google Scholar
• Connor DF, Findling RL, Kollins SH, Effects of guanfacine extended release, a nonscheduled alpha2A-adrenoceptor agonist, on oppositional symptoms in children aged 6 to 12 years with a diagnosis of attention-deficit/hyperactivity disorder and the presence of oppositional symptom. CNS Drugs 2010;24(9):755-68
   Google Scholar
• Biederman J, Melmed RD, Patel A, Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008;13:1047-55
   PubMed Web of Science ®Google Scholar
• Sallee FR, Lyne A, Wigal T, McGough J. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:215-26
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19(5):501-10
   Google Scholar
• Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 1985;24(5):617-29
   Google Scholar
• Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34(1):50-4
   Google Scholar
• Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38(12):1551-9
   Google Scholar
• Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921
   Google Scholar
• Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009;23(Suppl 1):43-9
   Google Scholar
• Pliszka SR, Crismon ML, Hughes CW, Texas consensus conference panel on pharmacotherapy of childhood attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45(6):642-57
   Google Scholar
• McBurnett K, Pfiffner LJ. Treatment of aggressive ADHD in children and adolescents: conceptualization and treatment of comorbid behavior disorders. Postgrad Med 2009;121(6):158-65
   Google Scholar
• Bangs ME, Hazell P, Danckaerts M, Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008;121(2):e314-20
   Google Scholar
• Dell'Agnello G, Maschietto D, Bravaccio C, Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol 2009;19(11):822-34
   Google Scholar
• Weiss M, Panagiotopoulos C, Giles L, A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol 2009;19(5):575-82
   Google Scholar